Compare AZN & WFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AZN | WFC |
|---|---|---|
| Founded | 1992 | 1852 |
| Country | United Kingdom | United States |
| Employees | N/A | 194369 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.0B | 258.3B |
| IPO Year | 1995 | 2020 |
| Metric | AZN | WFC |
|---|---|---|
| Price | $183.94 | $84.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 27 |
| Target Price | ★ $208.08 | $97.38 |
| AVG Volume (30 Days) | 2.8M | ★ 8.5M |
| Earning Date | 10-30-2026 | 10-13-2026 |
| Dividend Yield | 1.75% | ★ 2.32% |
| EPS Growth | N/A | ★ 16.57 |
| EPS | N/A | ★ 5.47 |
| Revenue | N/A | ★ $85,063,000,000.00 |
| Revenue This Year | $7.90 | $5.36 |
| Revenue Next Year | $6.38 | $5.34 |
| P/E Ratio | $31.91 | ★ $15.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $88.41 | $72.78 |
| 52 Week High | $212.71 | $97.76 |
| Indicator | AZN | WFC |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 50.13 |
| Support Level | $181.04 | $83.38 |
| Resistance Level | $193.52 | $86.17 |
| Average True Range (ATR) | 3.62 | 1.95 |
| MACD | -0.24 | 0.07 |
| Stochastic Oscillator | 66.48 | 27.00 |
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Wells Fargo is a premier, North American-focused banking titan that commands a $2.25 trillion balance sheet and the third-highest deposit market share in the United States. The bank uses a dense, expansive network of 4,079 branches to champion retail consumers and the middle market, where the firm has built a particularly strong reputation. Following the removal of its federal asset cap in 2025, the firm is set to deploy its legacy excess liquidity to expand each of its four segments: consumer & business lending, commercial banking, corporate & investment banking, and wealth & investment management.